In a significant advancement for clinical research, the Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards) has announced a pivotal expansion of its Winn Career Development Award (Winn CDA) program. For the first time, early-stage investigator-physicians specializing in neuropsychiatry are now eligible to apply for this prestigious award. This development underscores the program’s dedication to cultivating a diverse and inclusive network of clinical trialists who prioritize equitable access to cutting-edge medical research across all patient populations.
Established in 2020, the Winn CDA has been instrumental in equipping physician-scientists with the necessary skills to improve clinical trial design and execution—particularly emphasizing community engagement and representation. The program’s rigorous two-year curriculum supports scholars with a $240,000 award intended to safeguard nearly half of their professional time to focus exclusively on their research and training. This structure enables fellows to develop and lead clinical trials that are methodologically robust while ensuring that participant cohorts accurately reflect the demographics affected by the diseases under study.
Historically, the Winn CDA program has concentrated its focus on areas such as oncology and cardiovascular and cardiometabolic diseases, fields where disparities in clinical trial participation have been well-documented. Expanding into neuropsychiatry represents a strategic response to the persistent challenges of participant diversity within neurological and psychiatric clinical studies. Disorders like Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and schizophrenia often disproportionately affect underrepresented communities yet remain under-investigated within those groups.
Neuropsychiatric clinical research is rapidly evolving, utilizing advanced neuroimaging, biomarker discovery, and novel neurotherapeutic approaches to unravel the complexities of brain disorders. However, clinical trials in this domain have struggled with recruitment and retention of diverse patient cohorts, limiting the generalizability and applicability of findings. Megan Becker, Executive Director of the Winn CDA program, highlighted this disparity, emphasizing the program’s commitment to fostering trials that serve all communities equitably. The inclusion of neuropsychiatry in the Winn CDA is a direct effort to bridge this gap, cultivating investigators who prioritize inclusivity and community collaboration.
Ali Gemma, Program Director of Winn CDA, stressed the importance of recruiting neuropsychiatry researchers whose work aligns with diseases that impact millions worldwide yet suffer from limited clinical trial representation. By focusing on these critical conditions, Winn CDA aims to generate pivotal data that accurately reflects patient diversity, ultimately informing tailored therapeutic interventions and improving clinical outcomes. The program envisions training physician-scientists capable of designing trials that are not only scientifically rigorous but also community-oriented and culturally sensitive.
The Winn Awards program was established by the Bristol Myers Squibb Foundation and has since attracted additional support from industry leaders such as Gilead Sciences, Amgen, and Genentech. These partnerships are essential for maintaining the program’s sustainability and expanding its reach to new research frontiers. By leveraging these collaborations, Winn Awards ensures that its scholars have access to cutting-edge resources, mentorship, and networks necessary for driving innovations in clinical trial methodologies and improving patient representation.
Applicants interested in the Winn CDA’s newly broadened eligibility are encouraged to submit their proposals by May 4, 2026. Prospective candidates can expect comprehensive support from the Winn CDA team, which offers guidance on application procedures and tailored advice to help prepare competitive submissions. This open line of communication aims to reduce barriers for physician-scientists entering the field and enhance the quality of scientific inquiry within the program.
Clinical trial inclusivity remains a critical concern within medical research, as historically marginalized populations continue to face systemic obstacles that delay or prevent their participation in studies. The Winn CDA’s expansion into neuropsychiatry reflects an acknowledgment of these complexities and positions the program as a leader in fostering equitable and impactful research practices. By emphasizing multidisciplinary training and community engagement, Winn awards are addressing underlying structural inequities that hinder scientific progress and equitable healthcare delivery.
The program’s design incorporates hands-on mentorship alongside didactic training, giving investigators practical tools to navigate regulatory pathways, community partnerships, and data management challenges inherent in clinical trial conduct. Scholars receive mentorship from leaders with expertise in trial design, patient engagement, and health disparities research. This holistic approach ensures that Fellows emerge not only as capable researchers but as advocates for the populations they serve, equipped to make paradigm-shifting contributions in neuropsychiatric research.
With neuropsychiatric disorders posing escalating healthcare burdens globally, particularly among aging and underserved populations, the Winn CDA initiative’s timing could not be more critical. As clinical trials begin incorporating novel biomarkers, digital health technologies, and adaptive trial designs in neuropsychiatry, the need for investigators trained in inclusive, representative methodologies is paramount. Winn-trained physician-scientists are positioned to lead this new era, shaping trials that translate scientific discovery into tangible patient benefits, while dismantling long-standing barriers to clinical research participation.
Ultimately, the expansion of the Winn Career Development Award to encompass neuropsychiatry signals a transformative moment in clinical research training and funding. By investing in early-career physician-scientists who commit to equity and innovation, the program advances a future where clinical trials are more inclusive, research outcomes more reliable, and therapeutic breakthroughs accessible to all patients irrespective of background. The success of this initiative promises to accelerate progress in neuropsychiatry and serve as a model for other fields striving toward comprehensive representation and impact.
Those seeking more information about eligibility and application guidelines can reach out directly to the Winn CDA team at winncda@vcu.edu. Additional program details, updates, and resources are available on the official website at www.winnawards.org. With this expansion, the Robert A. Winn Excellence in Clinical Trials Award Program renews its commitment to fostering a generation of physician-scientists equipped to conduct better science for all — delivering innovations that truly represent and benefit diverse patient communities across the neuropsychiatric disease spectrum.
Subject of Research: Expansion of clinical trial training programs to include neuropsychiatry, focusing on improving trial representativeness and inclusivity in neurological disorders.
Article Title: Robert A. Winn Excellence in Clinical Trials Award Broadens Scope to Include Neuropsychiatry Researchers
News Publication Date: March 19, 2026
Web References:
- www.winnawards.org
Image Credits: Sara Furlong
Keywords: neuropsychiatry, clinical trials, research diversity, physician-scientists, neuropsychiatric disorders, Alzheimer’s disease, Parkinson’s disease, ALS, MS, schizophrenia, clinical trial inclusivity, community engagement, Robert A. Winn Excellence in Clinical Trials Award, Winn Career Development Award
